Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
Vincent Poher, Chief Executive Officer at BIOCELLIS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Thrombosis Research, adding:
“A little late in sharing this, but perhaps at the right time.
Last May, Thrombosis Research published the first full analytical and clinical validation of the Tsmart FIB Batrox assay on the LabPad Evolution platform.
The study demonstrated strong correlation with the laboratory Clauss method (r = 0.94), excellent diagnostic performance at the clinically critical 1 and 2 g/L thresholds (where it matters most for severe bleeding), and rapid quantitative fibrinogen measurement from citrated whole blood.
Importantly, the assay was also shown to be insensitive to major anticoagulants tested, including heparins and DOACs.
This last point is particularly important for us.
Our chemistry could make rapid fibrinogen measurement especially relevant in highly anticoagulated environments such as cardiac surgery, extracorporeal circulation and critical care, where every minute matters.
Congratulations to the entire team and all our clinical and scientific partners who contributed to this important milestone!
Following the acquisition of the key LabPad assets and technology by Biocellis, we are fully restarting the LabPad program.
This publication is therefore more than the conclusion of years of development.
It is the scientific foundation for a new chapter, with the ambition to bring LabPad back to the market and develop a broader point-of-care haemostasis platform.
And this is only the first of several clinical publications to come.
More to come!”
Title: Analytical and clinical validation of the Tsmart FIB Batrox assay on the LabPad Evolution analyzer for fibrinogen measurement in whole blood
Authors: Nina Breteau, Corinne Frère, Raphaël Marlu, Landry Seyve, Stéphane Blachier, Vincent Poher, Johanna Spiaczka, Benoît Polac
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE